|
Age at adjuvant radiotherapy (years)
| |
|
Mean/SD/median/range
|
64.8/5.81/65.3/75 - 54
|
|
Time from salvage lymph node dissection to adjuvant RT (months)
| |
|
Mean/SD/median/range
|
2.75/1.72/2.20/8.4 - 0.8
|
|
Region for adjuvant RT n (%)
| |
|
Pelvic right only
|
2/46 (4.3%)
|
|
Pelvic left only
|
5/46 (10.9%)
|
|
Pelvic only (left/right/bilateral)
|
26/46 (57%)
|
|
Retroperitoneal only
|
5/46 (11%)
|
|
Pelvic and retroperitoneal
|
14/46 (30%)
|
|
Retroclavicular and retroperitoneal
|
1/46 (2%)
|
|
Cases with dose escalation on involved region n (%)
|
11/46 (24.0%)
|
|
Method of adjuvant radiotherapy
| |
|
3D-conformal radiotherapy n (%)
|
29/46 (63%)
|
|
IMRT n (%)
|
17/46 (37.0%)
|
|
Concurrent radiation of prostatic fossa n (%)
|
12/46 (26.1%)
|
|
Total dose for radiation of prostatic fossa (Gy)
| |
|
Mean/SD/median/range
|
69.18/2.38/70.20/45.0 – 72.2
|
|
Duration of adjuvant radiotherapy (months)
| |
|
Mean/SD/median/range
|
1.39/0.35/1.37/2.4 – 1.0
|
|
Dose per fraction (Gy)
|
1.8, 5x1.8/week
|
|
Total dose for pelvic or retroperitoneal RT (Gy)
| |
|
Mean/SD/median/range
|
49.55/4.16/50.40/45.0 – 59.4
|
|
Number of cases with concurrent AHT at radiotherapy n (%)
|
2/46 (4.3%)
|
|
Patients with concurrent AHT at latest follow up
|
27/43 (62.8%)
|
|
Comorbidities at latest follow1 up n (%)
| |
|
Cardiovascular disease n (%)
|
10/38 (26.4%)
|
|
Diabetes mellitus n (%)
|
3/38 (7.9%)
|
|
Concurrent malignant disease n (%)
|
3/38 (7.9%)
|
|
Chronic disease/chronic pain n (%)
|
6/38 (15.9%)
|
